{"id":21,"date":"2023-11-03T18:42:27","date_gmt":"2023-11-03T18:42:27","guid":{"rendered":"https:\/\/sites.dundee.ac.uk\/farnaby-group\/?page_id=21"},"modified":"2025-09-22T15:02:24","modified_gmt":"2025-09-22T14:02:24","slug":"william-farnaby","status":"publish","type":"page","link":"https:\/\/sites.dundee.ac.uk\/farnaby-group\/william-farnaby\/","title":{"rendered":"Dr. William Farnaby"},"content":{"rendered":"\n
\"\"<\/figure>
\n

Will is a Principal Investigator within the University of Dundee Centre for Targeted Protein Degradation. He has recently been awarded EPSRC New Investigator and Wellcome Trust Early Career awards, supporting his long-term vision for using induced proximity chemistry to address and understand diseases of the central nervous system. Previously, Will led a large Targeted Protein Degradation drug discovery team, as part of a collaboration between the University of Dundee and Boehringer-Ingelheim. He has been a key contributor to major, highly cited advances in the field of targeted protein degradation and in particular in the area of structure based PROTAC design. Prior to this he co-invented multiple clinical candidates for CNS diseases as a medicinal chemist at Takeda, including the CH24Hi drug for Dravet syndrome, Soticlestat.<\/p>\n\n\n\n